Linde heads into Q3 earnings with analysts trimming targets but bulls still in charge

The lending market tells a straightforward story: shorts have essentially no foothold here. Short interest is 1.3% of the free float, low by any measure, and the borrow pool is vast, with availability well above 9,000%, meaning supply to borrow far exceeds current demand by an extraordinary margin. Cost to borrow has eased to 0.35%, its lowest level in six weeks, down roughly 32% over the past month. The ORTEX short score of 30.9 places LIN in the 66th percentile on short score rank, meaning it is more lightly shorted than most of its peers. There is no meaningful squeeze dynamic, no scarcity in the lending market, and no evidence of concentrated directional bets against the stock. Short interest has risen 14.8% over the past month in share terms, but from a base so small that the absolute level remains inconsequential.

Options positioning reflects a persistent preference for downside protection, though not at an extreme level. The put/call ratio of 1.35 is broadly in line with its 20-day average of 1.37, producing a z-score close to zero. This is a structurally put-heavy book rather than a tactical hedge. LIN's options market has run a PCR well above 1.0 throughout the past six weeks, with the 52-week high of 1.51 hit on September 28. That elevated reading has now normalised, and the current level suggests options traders are neither adding nor removing protection ahead of the October 29 print.

On valuation, LIN trades on a PE of 25.5 times and an EV/EBITDA of 16.7 times. Both have drifted modestly higher over the past month as the stock recovered. The EV/EBIT factor score sits at the 22nd percentile, confirming the market's premium pricing relative to peers, a long-standing feature of the stock rather than a recent shift. The dividend score ranks at the 99th percentile, and the EPS surprise score of 60 suggests a solid but not exceptional record on beating estimates. The bull case rests on consistent manufacturing volume growth, Asia-Pacific electronics-driven margin expansion and Linde's demonstrated ability to hold pricing. The bear case centres on U.S. healthcare headwinds, a potential volume drag in a global slowdown, and the ongoing pressure on merchant and packaged gas demand.

Wikipedia attention has risen sharply relative to the prior 90 days, with an attention z-score of 2.28 as of September 25, its highest reading in the recent period. This reflects retail interest in the name rather than a revenue signal, but it aligns with the stock's recent re-rating following a quiet August.

The recent earnings history is worth keeping in mind: the last two prints each produced a next-day decline of around 5.5% to 6.4%, with five-day reactions of minus 3.7% to 4.1%. LIN does not tend to bounce after misses. The October 29 release is 22 days away, and with the Street trimming targets but not ratings, the question heading into that print is whether the margin story in Asia-Pacific can offset continued softness in U.S. healthcare, and whether pricing holds in a more uncertain industrial demand environment.